What's Hot
View all perspectives
Janet Pope Janetbirdope
2 years 5 months ago
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
Richard Conway RichardPAConway
2 years 5 months ago
Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt
David Liew drdavidliew
2 years 5 months ago
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3
Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking!
POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
Aurelie Najm AurelieRheumo
2 years 5 months ago
↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx.
Adjusted on smoking status, age and BMI.
Shall we follow this group of patients more closely?
OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k
Aurelie Najm AurelieRheumo
2 years 5 months ago
🔜 Remission in PsA : the earlier the better ⏰
Dutch cohort (DEPAR) 300+pts
Failure to achieve MDA 1yr post diagnosis
🧨worst QoL yr 1️⃣2️⃣&3️⃣
🧨↗️bioDMARDs use over time
🧨no recovery
#OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP
David Liew drdavidliew
2 years 5 months ago
PMR bursas are filled with macrophage subtypes esp CD68+, expressing IL-6 & GM-CSF.
PMR is now far from just a vibe - real science, real targets for therapy.
Not every day that PMR basic science makes it on stage, lovely from @VasculitisUMCG @jiemy_william
#EULAR2022 @RheumNow https://t.co/zem3JEosQL
Richard Conway RichardPAConway
2 years 5 months ago
Jiemy et al. Phenotyping monocytes/macrophages in PMR. Synovial/bursal macrophages have pro-inflammatory phenotype with prominent IL-6 and GM-CSF response. Rationale for tocilizumab/mavrilimumab @RheumNow #EULAR2022 OP0015 https://t.co/53GJkL4BcP
Aurelie Najm AurelieRheumo
2 years 5 months ago
Retrospective nation-wide italian study:
Long term exposure to :
🌫 PM10 ⬆️ risk of RA aOR 1.4 but not other AI diseases
🚗PM2.5 ⬆️ risk of RA aOR 1.6 CTDs aOR 1.1 IBDs aOR 1.2
OP0071 #EULAR2022 @Rheumnow https://t.co/HOOEnh7KWW
TheDaoIndex KDAO2011
2 years 5 months ago
Pre-clinical RA TREAT EARLIER Trial: #Plenary OP0070
RDBPCT eval temporary MTX vs PCB in 136 pts with arthralgias >2 weeks at risk for RA (MRI hand/forefoot w/subclinical inflammation) followed for 2 yrs; 1/3 +ACPA. Rx 1 yr can delay but won’t prevent RA. #EULAR2022 @rheumnow https://t.co/v1GWOBFstz
Dr. John Cush RheumNow
2 years 5 months ago
EULAR 2022 Featured Industry Abstracts
Review is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
https://t.co/ggnAyuvAbl https://t.co/WjKDb70RkW
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found:
💠32% had a flare (new IS or Pred>9mg/d)
💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare
Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:
💠SLEDAI=>10
💠dsDNA+ve + ⬇️C3 and/ ⬇️C4
💠⬇️C3 and/ C4 pre-treatment
💠Response high regardless SDI, Steroid, #lupus duration
@RheumNow https://t.co/fLggazbRQu
Ashima Makol MD AshimaMakol
2 years 5 months ago
✨Localized #Scleroderma Pearls✨
#EULAR2022
Eosinophilic Fasciitis
👉Contractures wrists/ankles, rarely fingers
👉Mimics- #Lipodermatosclerosis #Panniculitis
👉GCs+MTX 1st line (IV in refractory🧐),MMF 2nd line
✅I add IVIg+/-UVA1 (pending logistics and insurance coverage!) https://t.co/ZErfLxgdxd
Richard Conway RichardPAConway
2 years 5 months ago
Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK
Poster Hall